Jul 01, 2021 / 12:00PM GMT
Operator
Good day, and welcome to the Immunic Therapeutics IMU-838 in Multiple Sclerosis Conference Call. (Operator Instructions) Please note this event is being recorded.
I'd now like to turn the conference over to Jessica Breu. Please go ahead.
Jessica Breu - Immunic, Inc. - Head of IR & Communications
Thank you, Jason. I also would like to welcome you to Immunic's conference call and webcast today to discuss our press release issued this morning to announce FDA clearance to begin with our Phase III ENSURE studies of IMU-838 in relapsing-remitting multiple sclerosis and our Phase II CALLIPER study of IMU-838 in progressive multiple sclerosis. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
Speaking on today's call are Dr. Daniel Vitt, our CEO and President; and Dr. Andreas Muehler, our Chief Medical Officer.
Before we begin, as always, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect,
Immunic Inc Discuss Overall MS Development Strategy - Corporate Call Transcript
Jul 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers